Athenex, Inc. Announces Commencement of Patient Enrollment for Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer
19 juil. 2017 08h00 HE
|
Athenex, Inc.
BUFFALO, N.Y., July 19, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex藥劑部獲得FDA許可證，可進口8.4%碳酸氫鈉注射液，解決美國藥品短缺
13 juil. 2017 07h15 HE
|
Athenex, Inc.
紐約州水牛城, July 13, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc.（NASDAQ:ATNX）是一間全球性的生物醫藥公司，致力於發掘、研發及商業化新型療法以治療癌症。今日，Athenex,...
Athenex Pharmaceutical Division Receives FDA Clearance to Import Sodium Bicarbonate 8.4% Injection to Address U.S. Drug Shortage
12 juil. 2017 09h00 HE
|
Athenex, Inc.
BUFFALO, N.Y., July 12, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc.宣布向中國藥監局提出Oraxol的新藥臨床試驗申請
05 juil. 2017 18h25 HE
|
Athenex, Inc.
紐約州水牛城, July 06, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc.（Nasdaq:...
Athenex, Inc. Announces Submission of Investigational New Drug Application of Oraxol to Chinese FDA
05 juil. 2017 07h00 HE
|
Athenex, Inc.
BUFFALO, N.Y., July 05, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc.宣布結束首次公開招股並已行使全部超額配股權
20 juin 2017 10h27 HE
|
Athenex, Inc.
美國紐約水牛城, June 20, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. ﹙美國納斯達克證券市場代號：ATNX﹚是一間環球性的生物醫藥公司，致力於發掘、研發及商業化新型療法以治療癌症。今日，Athenex,...
Athenex, Inc. Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option
19 juin 2017 16h05 HE
|
Athenex, Inc.
BUFFALO, N.Y., June 19, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc. 公布首次公開招股價格
15 juin 2017 00h39 HE
|
Athenex, Inc.
美國紐約州水牛城, June 15, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. ﹙Nasdaq：ATNX﹚是一間環球性的生物醫藥公司，致力於發掘、研發及商業化新型療法以治療癌症。今日，Athenex, Inc.公布首次發行共6百萬股普通股之公開招股價格，發售價為每股11.00 美元。此外，Athenex,...
Athenex, Inc. Announces Pricing of Initial Public Offering
14 juin 2017 07h00 HE
|
Athenex, Inc.
BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...